Drug news
Eisai re-submits perampanel to FDA for Epilepsy
Eisai has resubmitted a new drug application for its perampanel, for which it is seeking approval in this key market as an adjunctive therapy for partial onset seizures associated with Epilepsy.The FDA had issued a refusal to file letter for perampanel in July.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins